STAINES-UPON-THAMES, United
Kingdom, Dec. 2, 2019
/PRNewswire/ -- Mallinckrodt
plc (NYSE: MNK), a global biopharmaceutical company, announced
today that the Company now will present at the Piper Jaffray Annual
Healthcare Conference on Wednesday, Dec. 4,
2019 at 12:30 p.m.
Eastern.
Mark Trudeau, President and Chief
Executive Officer, and Steven
Romano, M.D., Executive Vice President and Chief Scientific
Officer, will represent the company in a fireside
chat.
Individuals who cannot attend the meeting in person can find
webcast information at: http://www.mallinckrodt.com/investors. A
replay will also be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; analgesics and gastrointestinal products. Its Specialty
Generics reportable segment includes specialty generic drugs and
active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution
of important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and
Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Media
Daniel Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. © 2019
Mallinckrodt. 12/19
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-moves-date-and-time-of-its-fireside-chat-at-piper-jaffray-annual-healthcare-conference-300967791.html
SOURCE Mallinckrodt plc